NCT03905655View on ClinicalTrials.gov

Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

March 10, 2021

Study Completion Date

October 11, 2021

Conditions
Chronic Hepatitis B
Interventions
DRUG

Placebo Oral Tablet

Number of placebo tablets administered orally depends on the arm

DRUG

Nitazoxanide

Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors
lead

Romark Laboratories L.C.

INDUSTRY

NCT03905655 - Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B | Biotech Hunter | Biotech Hunter